206 related articles for article (PubMed ID: 23771769)
21. [Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs].
Lange S
Z Evid Fortbild Qual Gesundhwes; 2015; 109(6):417-30. PubMed ID: 26474646
[TBL] [Abstract][Full Text] [Related]
22. [Effect of the German Act on the reform of the market for medicinal products (AMNOG) on the quality of neurological and psychiatric treatment].
Hamer H; Meyer-Lindenberg A
Nervenarzt; 2016 Apr; 87(4):351-2. PubMed ID: 27025218
[No Abstract] [Full Text] [Related]
23. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
Dabisch I; Dethling J; Dintsios CM; Drechsler M; Kalanovic D; Kaskel P; Langer F; Ruof J; Ruppert T; Wirth D
Health Econ Rev; 2014 Jan; 4(1):2. PubMed ID: 24460706
[TBL] [Abstract][Full Text] [Related]
24. The definition and role of quality of life in Germany's early assessment of drug benefit: a qualitative approach.
Lohrberg D; Augustin M; Blome C
Qual Life Res; 2016 Feb; 25(2):447-455. PubMed ID: 26242250
[TBL] [Abstract][Full Text] [Related]
25. [Significance of the German Act on the Reform of the Market for Medicinal Products for psychopharmacotherapy].
Gründer G
Nervenarzt; 2016 Apr; 87(4):356-66. PubMed ID: 26983820
[TBL] [Abstract][Full Text] [Related]
26. [Impact of early benefit assessment on patients with epilepsy in Germany: Current healthcare provision and therapeutic needs].
Strzelczyk A; Hamer HM
Nervenarzt; 2016 Apr; 87(4):386-93. PubMed ID: 26927680
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Adjusted and Unadjusted Indirect Comparison Methods in Benefit Assessment. A Simulation Study for Time-to-event Endpoints.
Kühnast S; Schiffner-Rohe J; Rahnenführer J; Leverkus F
Methods Inf Med; 2017 May; 56(3):261-267. PubMed ID: 28361159
[TBL] [Abstract][Full Text] [Related]
28. Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation.
Henschke C; Sundmacher L; Busse R
Health Policy; 2013 Mar; 109(3):263-9. PubMed ID: 23339876
[TBL] [Abstract][Full Text] [Related]
29. [The AMNOG and its consequences].
Dingermann T
Internist (Berl); 2013 Jun; 54(6):769-74. PubMed ID: 23475259
[TBL] [Abstract][Full Text] [Related]
30. INDUSTRY'S EXPERIENCES WITH THE SCIENTIFIC ADVICE OFFERED BY THE FEDERAL JOINT COMMITTEE WITHIN THE EARLY BENEFIT ASSESSMENT OF PHARMACEUTICALS IN GERMANY.
Dintsios CM; Schlenkrich S
Int J Technol Assess Health Care; 2018 Jan; 34(2):196-204. PubMed ID: 29455689
[TBL] [Abstract][Full Text] [Related]
31. [Subgroups in the early benefit assessment of pharmaceuticals: a methodical review].
Rasch A; Dintsios CM
Z Evid Fortbild Qual Gesundhwes; 2015; 109(1):69-78. PubMed ID: 25839372
[TBL] [Abstract][Full Text] [Related]
32. Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.
Herpers M; Dintsios CM
Eur J Health Econ; 2019 Feb; 20(1):45-57. PubMed ID: 29696458
[TBL] [Abstract][Full Text] [Related]
33. [Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures].
Bullinger M; Blome C; Sommer R; Lohrberg D; Augustin M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):283-90. PubMed ID: 25589357
[TBL] [Abstract][Full Text] [Related]
34. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Staab TR; Walter M; Mariotti Nesurini S; Dintsios CM; Graf von der Schulenburg JM; Amelung VE; Ruof J
Health Econ Rev; 2018 Sep; 8(1):23. PubMed ID: 30229501
[TBL] [Abstract][Full Text] [Related]
35. Shaping a suitable EU HTA dossier template: why the German template is not fit for purpose.
Schweitzer MK; Dold MN; Genet A; Gossens K; Klein-Hessling T; Löffler N; Rabel M; Rasch A; Reuter EM; Schmelcher J; Wolfram N; Werner S
Eur J Health Econ; 2024 Jul; 25(5):877-888. PubMed ID: 37843703
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
